mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2007-4-5-505-508mimmun-229Research ArticleКРАТКИЕ СООБЩЕНИЯSHORT COMMUNICATIONSКЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ СТАТИНОВ ПРИ РЕВМАТОИДНОМ АРТРИТЕ – ПИЛОТНОЕ ИССЛЕДОВАНИЕСLINICAL EFFICIENCY OF STATINS IN RHEUMATOID ARTHRITIS: A PILOT STUDYШиринскийИ. В.ShirinskyI. V.

лаборатория клинической иммунофармакологии

630099, г. Новосибирск, ул. Ядринцевская, 14. Тел./факс: 7 (3832) 28-25-47

ishirinsky@mail.ruЖелтоваО. И.ZheltovaO. I.

лаборатория клинической иммунофармакологии

ishirinsky@mail.ruСоловьеваН. Ю.SolovievaN. Yu.

лаборатория клинической иммунофармакологии

ishirinsky@mail.ruШиринскийВ. С.ShirinskyV. S.

лаборатория клинической иммунофармакологии

ishirinsky@mail.ruКозловВ. А.KozlovV. A.

лаборатория клинической иммунофармакологии

ishirinsky@mail.ruГУ НИИ клинической иммунологии СО РАМН, г. НовосибирскРоссия20071707201494-5505508Copyright © Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А., 20142014Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А.Shirinsky I.V., Zheltova O.I., Solovieva N.Y., Shirinsky V.S., Kozlov V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/229

Резюме. Статины используются для снижения уровня холестерина и профилактики сердечно-сосудистых заболеваний. В последние годы были открыты иммуномодулирующие и противовоспалительные свойства статинов, обосновывающие возможность их применения при аутоиммунных заболеваниях. Нами изучалась эффективность и безопасность симвастатина в дозе 40 мг/сут. при активном ревматоидном артрите (РА) на фоне приема стабильных доз болезнь-модифицирующих препаратов. После 12 недель терапии симвастатином было зарегистрировано статистически значимое снижение индекса активности болезни на 0,89 баллов, улучшение качества жизни и уменьшение уровня боли. Для подтверждения эффективности и безопасности симвастатина при активном РА требуется проведение крупномасштабных контролируемых рандомизированных испытаний.

Abstract. Statins are widely used to lower lipid levels and prevent cardiovascular disease. Recently described anti-inflammatory and immunomodulating properties of statins substantiate their application as a potentially novel treatment for autoimmune diseases. We evaluated efficacy and safety of simvastatin (40 mg daily) in patients with active rheumatoid arthritis (RA), as a supplement to stable doses of disease-modifying antirheumatic drugs. After 12 weeks of treatment, there was registered a significant decrease in disease activity score (by 0.89 points), improvement of life quality, and attenuation of pain levels. To confirm efficacy and safety of simvastatin in active RA, a large-scale controlled randomized study should be performed.

ревматоидный артрит3-гидрокси-3-метилглутарил-КоА-редуктазастатинылечениеrheumatoid arthritissimvastatinstatinstreatmentReferencesНасонов Е.Л. Иммунологические маркеры атеросклероза // Терапевт. арх. – 2002. – № 5. – С. 57-60.Насонов Е.Л. Иммунологические маркеры атеросклероза // Терапевт. арх. – 2002. – № 5. – С. 57-60.Чичасова Н.В., Насонова М.Б., Степанец О.В., Насонов Е.Л. Современные подходы к оценке активности ревматоидного артрита // Терапевт. арх. – 2002. – № 5. – С. 80-85.Чичасова Н.В., Насонова М.Б., Степанец О.В., Насонов Е.Л. Современные подходы к оценке активности ревматоидного артрита // Терапевт. арх. – 2002. – № 5. – С. 80-85.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial // Lancet. – 2002. – Vol. 360. – P. 7-22.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial // Lancet. – 2002. – Vol. 360. – P. 7-22.Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. – 2006. – Vol. 6. – P. 358-370.Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. – 2006. – Vol. 6. – P. 358-370.Koopman W.J., Arthritis and allied conditions // A Textbook of Rheumatology. – Philadelphia: Lippincot Williams and Wilkins, 2001.Koopman W.J., Arthritis and allied conditions // A Textbook of Rheumatology. – Philadelphia: Lippincot Williams and Wilkins, 2001.Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., McInnes I.B. A novel anti-inflammatory role for simvastatin in inflammatory arthritis // J. Immunol. – 2003. – Vol. 170. – P. 1524-1530.Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., McInnes I.B. A novel anti-inflammatory role for simvastatin in inflammatory arthritis // J. Immunol. – 2003. – Vol. 170. – P. 1524-1530.McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H.A., Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial // Lancet. – 2004. – Vol. 363. – P. 2015-2021.McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H.A., Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial // Lancet. – 2004. – Vol. 363. – P. 2015-2021.McCarey D.W., Sattar N., McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? // Arthritis Res. Ther. – 2005. – Vol. 7. – P. 55-61.McCarey D.W., Sattar N., McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? // Arthritis Res. Ther. – 2005. – Vol. 7. – P. 55-61.Meroni P.L., Luzzana C., Ventura D. Antiinflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? // Clin. Rev. Allergy Immunol. – 2002. – Vol. 23. – P. 263-277.Meroni P.L., Luzzana C., Ventura D. Antiinflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? // Clin. Rev. Allergy Immunol. – 2002. – Vol. 23. – P. 263-277.Palinski W., Napoli C. Unraveling pleiotropic effects of statins on plaque rupture // Thromb. Vasc. Biol. – 2002. – Vol. 22. – P. 1745-1750.Palinski W., Napoli C. Unraveling pleiotropic effects of statins on plaque rupture // Thromb. Vasc. Biol. – 2002. – Vol. 22. – P. 1745-1750.Seriolo B., Sulli A., Burroni A., Cutolo M. Rheumatoid arthritis and atherosclerosis // Reumatismo. – 2003. – Vol. 55. – P. 140-146.Seriolo B., Sulli A., Burroni A., Cutolo M. Rheumatoid arthritis and atherosclerosis // Reumatismo. – 2003. – Vol. 55. – P. 140-146.Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. – 2003. – Vol. 361. – P. 1149-1158.Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. – 2003. – Vol. 361. – P. 1149-1158.Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group // N. Engl. J. Med. – 1995. – Vol. 333. – P. 1301-1307.Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group // N. Engl. J. Med. – 1995. – Vol. 333. – P. 1301-1307.Si M.S., Reitz B.A., Borie D.C. Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123 // Invest. New Drugs. – 2005. – Vol. 23. – P. 21-29.Si M.S., Reitz B.A., Borie D.C. Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123 // Invest. New Drugs. – 2005. – Vol. 23. – P. 21-29.van Gestel A.M., Prevoo M.L., van’t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. – Vol. 39. – P. 34-40.van Gestel A.M., Prevoo M.L., van’t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. – Vol. 39. – P. 34-40.Watson D.J., Rhodes T., Guess H.A. Allcause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis or no arthritis in the UK General Practice Research Database // J. Rheumatol. – 2003. – Vol. 30. – P. 1196-1202.Watson D.J., Rhodes T., Guess H.A. Allcause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis or no arthritis in the UK General Practice Research Database // J. Rheumatol. – 2003. – Vol. 30. – P. 1196-1202.Wislowska M., Sypula S., Kowalik I. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker’s criteria, functional index, value of Waaler-Rose titre and duration of disease // Clin. Rheumatol. – 1998. – Vol. 17. – P. 369-377.Wislowska M., Sypula S., Kowalik I. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker’s criteria, functional index, value of Waaler-Rose titre and duration of disease // Clin. Rheumatol. – 1998. – Vol. 17. – P. 369-377.Wolfe F., Freundlich B., Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis // J. Rheumatol. – 2003. – Vol. 30. – P. 36-40.Wolfe F., Freundlich B., Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis // J. Rheumatol. – 2003. – Vol. 30. – P. 36-40.

The authors declare that there are no conflicts of interest present.